Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus (Q38174536)

30 August 2017

Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus (English)

1 reference

30 August 2017

1 reference

Uche Anadu Ndefo

1

1 reference

30 August 2017

Okwuchukwu Okoli

series ordinal

2

1 reference

30 August 2017

Goldina Erowele

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

1 January 2014

1 reference

American Journal of Health-System Pharmacy

30 August 2017

1 reference

30 August 2017

71

1 reference

30 August 2017

103-109

1 reference

30 August 2017

2

1 reference

Economic costs of diabetes in the U.S. In 2007.

30 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

[Pharmacological and clinical profile of alogliptin benzoate (NESINA®)]

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Incretin-based therapies for type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

Alogliptin benzoate for the treatment of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130131

31 March 2020

Identifiers

DOI

10.2146/AJHP130131

1 reference

30 August 2017

1 reference